Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Aprepitant safe for subacute sclerosing panencephalitis, but efficacy yet to be determined

08 Sep 2020

Aprepitant is safe and well-tolerated for the treatment of subacute sclerosing panencephalitis (SSPE), a recent study has found. Aside from modest improvements in electroencephalography (EEG) outcomes, no strong clinical effect was observed.

Researchers conducted a randomized, double-blind, placebo-controlled study on 62 patients with SSPE. Thirty-one (median age, 18 years) were allocated to the aprepitant arm, and the remaining 31 (median age, 22 years) received a placebo. Safety and tolerability were set as primary endpoints, while efficacy, defined as clinical improvement or stabilization, was set as a secondary outcome.

During the first 6 months, 15 patients dropped out, though mostly voluntarily; one withdrew due to side-effects, and another patient died. During the second 6 months, 12 more patients dropped out, one of whom died.

There were nine serious adverse events necessitating hospitalization. These included pneumonia (five in the aprepitant arm, three in controls) and cellulitis (one in the aprepitant arm). One case of hypotension and another of somnolence were recorded as treatment-associated adverse events.

The SSPE scoring system (SSS) was used as the main measure of neurological state. SSS did not significantly differ between arms at any time point, and neither did any of its domains: cognitive functions, seizures, motor functions, pyramidal functions, and speech capacity, among others.

Imaging, on the other hand, found some signals of efficacy in favour of aprepitant. EEG scores before the treatment and up to the 6-month follow-up were comparable in both groups. Twelve-months post-treatment, however, EEG scores were significantly better in the aprepitant patients (p=0.015).

Cerebral atrophy nevertheless worsened in both groups after 6 months of follow-up. Greater atrophy correlated nonsignificantly with poorer EEG scores.

Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.